Welcome to our dedicated page for Kailera Therapeutics SEC filings (Ticker: KLRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kailera Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kailera Therapeutics's regulatory disclosures and financial reporting.
Kailera Therapeutics, Inc. director, CEO & President Ronald C. Renaud Jr. was granted stock options linked to the company’s common stock. The Form 4 shows two awards of stock options, each covering 300,000 shares at an exercise price of $16.00 per share, expiring on April 16, 2036.
One option grant vests 25% on April 16, 2027 and then in 36 equal monthly installments, as long as he continues in service. The second grant vests only if the stock reaches $40 per share during a defined performance period or in a qualifying change in control, also requiring continued service through vesting.
Kailera Therapeutics reported that officer Paul D. Burgess received two grants of stock options, each covering 100,000 shares of common stock at an exercise price of $16.00 per share. These are compensation awards, not open‑market purchases.
One option grant vests over time, with 25% vesting on April 16, 2027 and the remainder in 36 equal monthly installments, subject to continued service. The second grant vests only if the company’s stock price reaches $40 during a defined performance period or in a qualifying change in control, with both awards expiring on April 16, 2036.
Kailera Therapeutics, Inc. reported that director John F. Milligan received a grant of stock options covering 38,300 shares of common stock. The options have an exercise price of $16.00 per share and expire on April 16, 2036.
The options vest and become exercisable in full on April 16, 2027, as long as Milligan continues to serve the company through that date. Following this grant, he holds stock options for 38,300 underlying shares directly.
Kailera Therapeutics, Inc. reported that Chief Commercial Officer Jamie Beth Coleman received two stock option awards, each covering 75,000 shares of common stock at an exercise price of $16 per share.
One option vests 25% on April 16, 2027 and then in 36 equal monthly installments, conditioned on continued service. The second option vests only if, during the period from October 16, 2026 to April 16, 2030, the company’s stock trades at or above $40 per share for 30 consecutive trading days or reaches at least $40 per share in a qualifying change in control, also subject to continued service.
Kailera Therapeutics director Martin Mackay received a new stock option grant. On April 16, 2026, he was granted options to acquire 38,300 shares of Common Stock at an exercise price of $16.00 per share.
The options were granted as compensation, not through an open‑market purchase or sale, and are held directly. They vest and become exercisable for 100% of the underlying shares on April 16, 2027, subject to his continued service. Following this grant, he holds 38,300 stock options, which expire on April 16, 2036.
Kailera Therapeutics, Inc. granted Chief Medical Officer Scott M. Wasserman two stock option awards, each covering 100,000 shares of common stock at an exercise price of $16.00 per share and expiring on April 16, 2036.
One option grant vests 25% on April 16, 2027 and then in 36 equal monthly installments, contingent on continued service. The other becomes exercisable only if the company’s stock price reaches at least $40 per share during a defined performance measurement period or in a qualifying change in control, also subject to continued service.
Kailera Therapeutics, Inc. director Christopher Hite received a grant of stock options covering 38,300 shares of common stock. The options have an exercise price of $16.00 per share and expire on April 16, 2036.
The options vest and become exercisable for 100% of the underlying 38,300 shares on April 16, 2027, subject to his continued service through that date. This is a compensation-related award, not an open-market purchase or sale of shares.
Kailera Therapeutics, Inc. director Frank Clyburn received a grant of stock options on April 16, 2026. The award covers 38,300 options to buy common stock at an exercise price of $16.00 per share, all held as direct ownership.
Following this grant, Clyburn holds 38,300 stock options. According to the terms, the options vest and become exercisable for 100% of the underlying shares on April 16, 2027, provided he continues to serve the company through that vesting date. The options are scheduled to expire on April 16, 2036 if not exercised.
Kailera Therapeutics, Inc. Chief Financial Officer Douglas W. Pagan reported two compensatory stock option grants. Each award covers 100,000 shares of common stock at an exercise price of $16.00 per share and expires on April 16, 2036.
One option grant vests 25% on April 16, 2027 and then in 36 substantially equal monthly installments, conditioned on continued service. The second option grant vests, if at all, only if the company’s stock price reaches $40 per share during a defined performance period or in a qualifying change in control, also subject to continued service.
Kailera Therapeutics, Inc. completed its initial public offering, selling 44,921,875 shares of common stock, including 5,859,375 additional shares purchased by the underwriters, at $16.00 per share. The IPO generated gross proceeds of $718.8 million before underwriting discounts and expenses.
In connection with the IPO, Kailera filed a new amended and restated certificate of incorporation and adopted amended and restated bylaws. These governance changes increase authorized common stock to 800,000,000 shares, authorize 10,000,000 shares of undesignated preferred stock, create a classified board with three-year staggered terms, limit director removal to for-cause by a two‑thirds stockholder vote, restrict stockholder written consents, and add Delaware and federal court exclusive forum provisions for specified disputes.